Not available
Quote | Immutep Limited (NASDAQ:IMMP)
Last: | $2.60 |
---|---|
Change Percent: | -2.7% |
Open: | $2.66 |
Close: | $2.60 |
High: | $2.66 |
Low: | $2.55 |
Volume: | 246,851 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Immutep Limited (NASDAQ:IMMP)
2024-04-24 16:08:47 ET More on Immutep Seeking Alpha’s Quant Rating on Immutep Historical earnings data for Immutep Financial information for Immutep Read the full article on Seeking Alpha For further details see: Immutep reports promising ...
2024-04-24 10:00:42 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance BofA watched clients retract $2B last week as the S&P dropped ...
Message Board Posts | Immutep Limited (NASDAQ:IMMP)
Subject | By | Source | When |
---|---|---|---|
MomentumIts trading | make it happen | investorshub | 05/15/2023 2:39:54 AM |
short squeeze article | make it happen | investorshub | 05/14/2023 9:17:55 PM |
$IMMP The gaining | everything | investorshub | 05/12/2023 7:52:42 AM |
Price gaining last trade up | stocks2watch | investorshub | 05/09/2023 1:11:31 PM |
$IMMP bulls and bears | calahan67 | investorshub | 04/28/2023 1:37:20 PM |
News, Short Squeeze, Breakout and More Instantly...
Immutep Limited Company Name:
IMMP Stock Symbol:
NASDAQ Market:
Wednesday, Immutep Limited (NASDAQ:IMMP) released preliminary topline results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) P...
Media Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9% response rate, the primary endpoint of the study Data collection, cleaning, and analysi...
Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune diseases CHDR will utilize its unique challe...